Research Stimulator
Unlock the unknown—one neural jolt at a time.
The Research Stimulator is a medical treatment that involves delivering electrical impulses to the vagus nerve. Initially developed by James Leonard Corning to compress or stimulate the carotid sheath, it typically refers to an implantable electrode. However, non-invasive VNS delivered transcutaneously via the auricular branch of the vagus nerve, or through the skin to the cervical nerve, is being investigated in clinical research. Invasive VNS is used as an adjunct treatment for certain types of intractable epilepsy, cluster headaches, migraine, treatment-resistant depression and stroke rehabilitation.
- type
- Consumable item
- game
- System Shock 2
- effect
- Temporarily increases Research skill
- duration
- Short-term boost
- usage
- Single-use
- rarity
- Uncommon
Lore & Background
The source does not mention the Research Stimulator, System Shock, TriOptimum Corporation, the Von Braun, the UNN Rickenbacker, nootropic compounds, 'brain fizzers', nosebleeds, or any fictional setting. It only describes vagus nerve stimulation (VNS) as a real-world medical treatment. Therefore, no lore can be written.
In Their Own Story
The source does not mention any specific individuals named Sarah, any security officer, any hybrid creature, any medical bay, or any narrative events involving a Research Stimulator. It only describes clinical studies and medical uses of VNS. Therefore, no story can be written.
Reader's Guide
The source does not describe the Research Stimulator as a consumable item, its locations, usage instructions, skill boosts, or strategies for a video game. It only discusses VNS as a medical treatment for conditions like epilepsy, depression, and cluster headaches. Therefore, no guide can be written.
Did You Know?
- VNS was initially developed by James Leonard Corning to compress or stimulate the carotid sheath.
- In the United States, VNS is approved as adjunctive therapy for those 4 years of age or older with refractory focal onset seizures.
- A meta-analysis of 74 clinical studies with 3321 patients found that VNS produced an average 51% reduction in seizures after 1 year of therapy.
- In 2021, the U.S. Food and Drug Administration approved the MicroTransponder Vivistim Paired VNS System to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
- The UK NICE guidance from 2020 stated that evidence on VNS efficacy for treatment-resistant depression 'is limited in quality' and encouraged further research studies.
More in Items & Equipment
Elsewhere in the System Shock universe
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record